Harrow (HROW) Operating Expenses (2010 - 2026)
Harrow's (HROW) quarterly Operating Expenses came in at $49.1 million in Q1 2026, up 12.83% year-on-year from $43.5 million in Q1 2025, and down 10.74% quarter-over-quarter from $55.0 million in Q4 2025.
Harrow (HROW) Operating Expenses (2010 - 2026) Analysis & Trends
Harrow's Operating Expenses history runs 17 years deep, the most recent figure standing at $49.1 million for Q1 2026.
- On a quarterly basis, Operating Expenses rose 12.83% year-over-year to $49.1 million in Q1 2026; TTM through Mar 2026 was $179.4 million, a 16.43% increase from a year earlier, with the FY2025 full-year figure at $173.9 million, up 22.82% from the prior year.
- Operating Expenses slipped to $49.1 million in Q1 2026 per HROW's latest filing, from $55.0 million in the prior quarter.
- Across five years, Operating Expenses topped out at $55.0 million in Q4 2025 and bottomed at $14.1 million in Q1 2022.
- The 5-year median for Operating Expenses is $31.0 million (2024), against an average of $30.3 million.
- Across the five-year window, Operating Expenses decreased 7.35% in 2022 and surged 87.73% in 2023, its largest moves.
- Year by year, Operating Expenses stood at $15.9 million in 2022, then jumped by 87.73% to $29.9 million in 2023, then jumped by 32.98% to $39.8 million in 2024, then soared by 38.28% to $55.0 million in 2025, then dropped by 10.74% to $49.1 million in 2026.
- Per Business Quant, the three latest HROW Operating Expenses figures stand at $49.1 million (Q1 2026), $55.0 million (Q4 2025), and $39.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 1.00 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 788.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 12.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 455.70 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.24 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 621.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 494.00 Mn |
| 10 | Harrow | 1.56 Bn | 1.47 Bn | 27.05 Mn | 49.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 49.13 Mn |
| Dec 31, 2025 | 55.03 Mn |
| Sep 30, 2025 | 39.18 Mn |
| Jun 30, 2025 | 36.10 Mn |
| Mar 31, 2025 | 43.54 Mn |
| Dec 31, 2024 | 39.80 Mn |
| Sep 30, 2024 | 35.92 Mn |
| Jun 30, 2024 | 34.87 Mn |
| Mar 31, 2024 | 30.96 Mn |
| Dec 31, 2023 | 29.93 Mn |
| Sep 30, 2023 | 22.45 Mn |
| Jun 30, 2023 | 21.12 Mn |
| Mar 31, 2023 | 16.62 Mn |
| Dec 31, 2022 | 15.94 Mn |
| Sep 30, 2022 | 16.20 Mn |
| Jun 30, 2022 | 15.10 Mn |
| Mar 31, 2022 | 14.06 Mn |
| Dec 31, 2021 | 16.86 Mn |
| Sep 30, 2021 | 17.48 Mn |
| Jun 30, 2021 | 9.55 Mn |